Ignite Creation Date:
2024-05-06 @ 11:01 AM
Last Modification Date:
2024-10-26 @ 12:38 PM
Study NCT ID:
NCT03409614
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-04-25
First Post:
2018-01-10
Brief Title:
Combinations of Cemiplimab Anti-PD-1 Antibody and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer
Sponsor:
Organization:
Regeneron Pharmaceuticals